1. Introduction and Background
Growth hormone-releasing hormone (GHRH) is a hypothalamic neuropeptide first isolated and characterised in the early 1980s, comprising 44 amino acid residues with full biological activity residing in the N-terminal 29-residue fragment (Mayo et al., 1983). GHRH serves as the principal stimulatory regulator of growth hormone (GH) synthesis and secretion from anterior pituitary somatotroph cells, operating in a pulsatile manner counterbalanced by the inhibitory tone of somatostatin. The therapeutic potential of augmenting this physiological axis has motivated the development of structurally modified GHRH analogues with improved pharmacokinetic properties relative to the native peptide, which is subject to rapid enzymatic degradation in circulation with a plasma half-life of approximately 6 to 8 minutes.
Tesamorelin (developmental designation TH9507) represents one such structurally modified analogue, developed originally by Theratechnologies Inc. (Montreal, Canada). Unlike other GHRH analogues that rely solely upon amino acid substitutions for protease resistance, tesamorelin employs a distinctive chemical modification: the conjugation of a trans-3-hexenoic acid moiety to the tyrosine residue at position 1 of the human GHRH(1-44) sequence (Dhillon, 2011). This N-terminal lipophilic modification differentiates tesamorelin from other GHRH-based compounds such as sermorelin and CJC-1295, and confers enhanced stability against aminopeptidase activity while preserving the full-length 44-amino acid sequence necessary for receptor engagement. The present review examines the molecular pharmacology, mechanism of action, and principal areas of published research involving tesamorelin, encompassing lipodystrophy, hepatic fat metabolism, and cognitive function.
2. Molecular Structure and Mechanism of Action
2.1 Structural Basis of the Trans-3-Hexenoic Acid Modification
Tesamorelin consists of the complete human GHRH(1-44)NH2 sequence with the addition of a trans-3-hexenoic acid group covalently linked to the alpha-amino group of the N-terminal tyrosine residue. This six-carbon unsaturated fatty acid chain introduces steric hindrance at the N-terminus, the primary site of enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) and other aminopeptidases (Dhillon, 2011). The modification does not alter the peptide's core amino acid sequence, thereby maintaining the native conformational properties required for high-affinity binding to the GHRH receptor. This design philosophy, preserving the endogenous sequence while conferring metabolic stability through a non-peptidic modification, distinguishes tesamorelin from analogues that achieve protease resistance through D-amino acid substitutions or backbone modifications.
2.2 GHRH Receptor Pharmacology and Pulsatile GH Secretion
Tesamorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a class B1 G protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Receptor activation initiates the Gs-adenylyl cyclase-cyclic AMP (cAMP) signalling cascade, resulting in protein kinase A-mediated phosphorylation events that promote GH gene transcription, GH biosynthesis, and the exocytotic release of GH from secretory granules (Mayo et al., 1983). A pharmacologically significant characteristic of GHRH receptor-mediated stimulation is the preservation of physiological GH pulsatility. Studies in healthy male subjects have demonstrated that tesamorelin administration augments endogenous GH pulse amplitude without disrupting the underlying ultradian secretory rhythm governed by hypothalamic somatostatin oscillations (Stanley et al., 2011). This amplification of pulsatile GH output, rather than imposition of tonic non-pulsatile GH elevation, represents a mechanistic distinction from exogenous recombinant GH administration, as downstream target-tissue responses including hepatic insulin-like growth factor I (IGF-1) production and adipose tissue lipolysis are differentially sensitive to the temporal pattern of GH exposure.
The selectivity of tesamorelin for the GHRH receptor means that its biological effects are confined to the somatotropic axis. Unlike growth hormone secretagogues acting through the ghrelin receptor (GHS-R1a), tesamorelin does not stimulate adrenocorticotropic hormone (ACTH), prolactin, or cortisol secretion at physiological doses, a feature that limits off-target endocrine effects and has been noted across multiple clinical investigations (Spooner and Olin, 2012).
3. Research in HIV-Associated Lipodystrophy
3.1 Background and Rationale
HIV-associated lipodystrophy syndrome encompasses a spectrum of body composition abnormalities observed in patients receiving antiretroviral therapy, characterised by pathological accumulation of visceral adipose tissue (VAT), often accompanied by peripheral fat wasting. The excess visceral adiposity is associated with metabolic disturbances including dyslipidaemia, insulin resistance, and elevated cardiovascular risk markers. The recognition that GH deficiency and relative GH insufficiency are prevalent in this population, and that GH exerts potent lipolytic effects in visceral adipose depots, provided the mechanistic rationale for investigating GHRH-based therapies as a means to reduce pathological visceral fat accumulation.
3.2 Pivotal Clinical Trials
The foundational clinical evidence for tesamorelin in HIV-associated lipodystrophy derives from two large-scale randomised, double-blind, placebo-controlled trials. The first, published in the New England Journal of Medicine, enrolled 412 HIV-infected patients with central fat accumulation and demonstrated that 26 weeks of daily subcutaneous tesamorelin (2 mg) produced a statistically significant reduction in trunk fat as measured by computed tomography, with an observed mean decrease in VAT of approximately 15% compared to a 5% increase in the placebo group (Falutz et al., 2007). IGF-1 levels increased significantly in the treatment group, consistent with the pharmacological mechanism of GHRH receptor-mediated GH axis stimulation. Importantly, the study reported that tesamorelin did not adversely affect glucose homeostasis as measured by fasting glucose and haemoglobin A1c, a finding of particular relevance given the known diabetogenic potential of supraphysiological GH exposure.
A subsequent confirmatory trial involving 405 patients replicated these findings over a similar 26-week treatment period, demonstrating a reduction in VAT of approximately 18% in the tesamorelin group versus placebo (Falutz et al., 2010). This trial additionally reported improvements in patient-reported body image distress and lipid parameters, including reductions in triglycerides and total cholesterol-to-high-density lipoprotein cholesterol ratio. Both trials noted that the VAT reductions observed during active treatment were reversed upon discontinuation, suggesting that the metabolic effects of tesamorelin require sustained GHRH receptor stimulation rather than reflecting a permanent alteration of adipose tissue biology. This observation carries implications for understanding the pharmacodynamic relationship between pulsatile GH augmentation and visceral adipose tissue metabolism.
4. Hepatic Fat and Non-Alcoholic Fatty Liver Disease Research
Extending beyond visceral adiposity, a growing body of research has examined the effects of tesamorelin on hepatic fat accumulation. Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in HIV-infected populations and is associated with progressive fibrosis, yet targeted pharmacological interventions remain limited. Stanley and colleagues conducted a randomised controlled trial in HIV-infected individuals with abdominal fat accumulation, using proton magnetic resonance spectroscopy to quantify intrahepatic lipid content. After 12 months of tesamorelin treatment, the intervention group demonstrated a significant reduction in hepatic fat fraction, with the proportion of patients meeting criteria for hepatic steatosis (intrahepatic lipid content greater than 5%) decreasing substantially relative to the placebo group, in which hepatic fat content increased (Stanley et al., 2014).
These hepatic findings are noteworthy for several reasons. First, the reduction in liver fat occurred independently of changes in overall body weight, suggesting a specific effect on hepatic lipid metabolism rather than a non-specific consequence of caloric deficit. Second, the magnitude of hepatic fat reduction was clinically meaningful, with several participants transitioning from steatotic to non-steatotic classifications during the treatment period. Subsequent analyses from this group examined whether baseline characteristics could predict fibrosis progression in HIV-associated NAFLD, identifying metabolic syndrome components and higher baseline hepatic fat fraction as significant predictors (Fourman et al., 2021). These data have informed ongoing interest in whether GHRH-mediated GH axis augmentation might modulate hepatic lipogenesis, fatty acid oxidation, or very-low-density lipoprotein secretion pathways, though the precise intrahepatic mechanisms remain subjects of active investigation.
5. Cognitive Function and Neuroprotection Research
A separate line of inquiry has explored the relationship between GHRH administration and cognitive function, motivated by the observation that the GH-IGF-1 axis declines with advancing age in parallel with cognitive deterioration, and that IGF-1 exerts well-characterised neurotrophic, neuroprotective, and neuromodulatory effects in the central nervous system. Baker and colleagues conducted a randomised, double-blind, placebo-controlled trial examining the effects of a GHRH analogue (tesamorelin) administered daily for 20 weeks in adults with mild cognitive impairment (MCI) and healthy older adults (Baker et al., 2012). The study reported that GHRH treatment was associated with favourable effects on executive function and a composite cognitive score in both healthy older adults and those with MCI, with the most pronounced improvements observed in measures of executive function, verbal memory, and processing speed.
Several mechanistic hypotheses have been proposed to account for these cognitive effects. IGF-1 receptors are densely expressed in hippocampal and cortical regions critical for memory and executive processing, and IGF-1 signalling has been implicated in synaptic plasticity, neurogenesis, and amyloid-beta clearance. The augmentation of circulating IGF-1 through GHRH receptor stimulation may therefore enhance central nervous system IGF-1 availability, although the degree to which peripherally elevated IGF-1 translates to functionally relevant changes in brain IGF-1 signalling remains an area of ongoing research. It should be noted that the cognitive trial employed a relatively small sample size, and the findings, while suggestive, require replication in larger, adequately powered studies with extended follow-up to determine whether the observed cognitive benefits are sustained and clinically meaningful.
6. Current Research Directions and Emerging Questions
Contemporary research involving tesamorelin continues to expand along several trajectories. In the metabolic domain, investigators are examining the long-term consequences of sustained GHRH receptor stimulation on cardiovascular risk biomarkers, including inflammatory mediators and markers of endothelial function, in populations with elevated cardiometabolic risk (Falutz et al., 2010). The observation that tesamorelin reduces both visceral and hepatic fat without producing clinically significant glucose intolerance has prompted interest in its potential relevance to broader populations with metabolic syndrome and NAFLD beyond the HIV-infected cohort in which it was originally studied (Stanley et al., 2014).
Neuroscience research continues to probe the relationship between GH axis augmentation and cognitive resilience in ageing. The tantalising findings from the Baker et al. trial have stimulated interest in larger-scale studies examining whether GHRH-based interventions might slow cognitive decline or modify Alzheimer's disease biomarker trajectories, though such investigations remain in early stages. The question of whether pulsatile GH augmentation offers a different neurocognitive profile compared with direct GH or IGF-1 administration represents an important mechanistic question with potential therapeutic implications (Baker et al., 2012).
From a pharmacological perspective, the distinctive trans-3-hexenoic acid modification of tesamorelin has renewed interest in lipophilic N-terminal modifications as a strategy for peptide stabilisation. Comparative studies examining the pharmacokinetic profiles, receptor binding kinetics, and downstream signalling characteristics of tesamorelin relative to other GHRH analogues (including CJC-1295 and sermorelin) may yield insights into the structure-activity relationships governing GHRH receptor pharmacology (Dhillon, 2011). Additionally, the reversibility of tesamorelin's effects upon cessation raises fundamental questions about the mechanisms by which pulsatile GH augmentation modulates visceral adipocyte biology and whether combination strategies might produce more durable metabolic outcomes.
7. Conclusion
Tesamorelin occupies a distinctive position within the GHRH analogue landscape by virtue of its unique trans-3-hexenoic acid modification and its full-length retention of the endogenous GHRH(1-44) sequence. Published research has established its capacity to augment pulsatile GH secretion through selective GHRH receptor agonism, with documented effects on visceral adipose tissue reduction (Falutz et al., 2007), hepatic fat modulation (Stanley et al., 2014), and preliminary evidence of cognitive benefits (Baker et al., 2012). The preservation of physiological GH pulsatility, the selectivity for the somatotropic axis, and the absence of significant glucose dysregulation in clinical trials collectively characterise tesamorelin's pharmacological profile. As research continues to elucidate the broader implications of GHRH receptor stimulation across metabolic, hepatic, and neurological domains, tesamorelin remains a compound of considerable investigational interest. This article is presented for educational and informational purposes only. All peptide compounds discussed are intended solely for legitimate scientific research conducted in accordance with applicable regulations and institutional guidelines.